ecrets of life, such as disease mechanisms and pathways, in some cases translating findings into drug targets or other products. Intellectual Property As of December 31, 2015, the company owned 298 issued patents in the United States, 199 issued patents in Germany and 1,234 issued patents in other major industrialized countries. The company had 859 pending patent applications. Regulations Other Fraud and Abuse Laws The company must comply with a variety of other laws, such as laws prohibiting false claims for reimbursement under Medicare and Medicaid, all of which can also be triggered by violations of federal anti-kickback laws; the Health Insurance Portability and Accounting Act of 1996, which makes it a federal crime to commit healthcare fraud and make false statements; and the Federal Trade Commission Act and similar laws regulating advertisement and consumer protections. Competition The company’s competitors include Promega Corp.; EMD Millipore or Merck Millipore; Macherey-Nagel GmbH; Thermo Fisher; Promega Corp.; Sigma-Aldrich Corp.; Roche Diagnostics; Abbott; Siemens; Cepheid; and Hologic. Significant Events In April 2016, Qiagen NV announced a partnership with Mirati Therapeutics, Inc. to co-develop and commercialize a companion diagnostic test to guide the use of Mirati's glesatinib (MGCD265), a targeted therapy under development for non-small cell lung cancer (NSCLC). The companies aim to create a regulator-approved test to personalize treatment decisions in NSCLC by detecting RNA biomarkers produced by exon 14 skipping mutations of the MET gene. In May 2016, QIAGEN N.V. announced that the company has entered into a licensing and co-development agreement with Therawis Diagnostics GmbH to develop and commercialize predictive assays in oncology. In September 2016, QIAGEN N.V. and the International Commission on Missing Persons announced collaboration on a project to enhance ICMP's ability to identify missing persons using next-generation sequencing (NGS) technologies. History QIAGEN N.V. was founded in 1986.
qiagen n.v. (QGEN:NASDAQ GS)
Venlo, 5912 PL
Phone: 31 77 355 6600
Fax: 31 77 355 6658www.qiagen.com
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for QGEN.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact QIAGEN N.V., please visit www.qiagen.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.